LYTIR

Insider · SEC Form 4 · Chief Accounting Officer

Louise Frederika Kooij

Filed with the SEC as Kooij Louise Frederika; the order above is the one the filer's own signature uses.

In the 12 months to Nov 8, 2026, on the open market: sold $4.4M of NAMS. Filed a median of 2 business days after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $4.4M in total.Jun: Insider sales $1.2MJul: Insider sales $3.2MDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $0Insider sales below: $4.4M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
  1. NAMSSold: NewAmsterdam Pharma Co N.V. Jul 20, 2026 105,000 shares filed Jul 22, 2026 3 transactions 10b5-1 plan filing $3.2M
  2. NAMSSold: NewAmsterdam Pharma Co N.V. Jun 22, 2026 40,000 shares filed Jun 24, 2026 2 transactions 10b5-1 plan filing $1.2M

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Other Form 4 entries

Not counted above: entries this filer reported on Form 4 in the same 12 months that are not open-market purchases or sales. Each entry is one line of a filing.

  • NAMS: option exercise or conversion (code M), 4 entries, Jun 22 to Jul 20, 2026
Code M
An exercise or conversion of a derivative security received from the company, such as stock options.

Source: the same SEC Form 4 filings. The codes are the SEC's own transaction codes; the meanings above are a plain-words reading of the SEC's Form 4 instructions.